TEGMINE THERAPEUTICS
Updated 67 days ago
4104 24th St., Suite PMB 405 San Francisco, CA 94114 USA
At Tegmine we target glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. We've engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Our proprietary TegMinerâ„¢ platform enables the discovery of unique cancer epitopes and allows us to develop these life-changing new antibodies for patients with unmet needs.
Associated domains: tegminetherapeutics.com